rhL
Rhizen Pharmaceuticals S.A. Announces Presentations on Tenalisib (RP6530) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
29 mai 2018 07h00 HE | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, May 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., a clinical-stage biotechnology company developing Tenalisib (RP6530), a highly selective and orally...
Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today...
New Logo.png
PROVECTUS ANNOUNCES PRELIMINARY RESULTS FROM PHASE 1B TRIAL OF INTRALESIONAL PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF STAGE IV MELANOMA
18 oct. 2017 09h38 HE | Provectus Biopharmaceuticals Inc.
– Adverse events consistent with established patterns for each drug; no unexpected toxicities observed – 50% overall objective response rate; 10% complete response; highest responses observed in...
Logo-BCC-Research.jpg
Liquid Biopsy Tools, Diagnostics Market to Reach $4.5B by 2022
10 oct. 2017 15h45 HE | BCC Research
WELLESLEY, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Liquid biopsy is rapidly gaining traction as a supplement or alternative to tissue biopsy, with the potential to attain a global market value of...
Biotherapharma_logo.jpg
Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)
23 févr. 2017 09h00 HE | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in...